Journals / Türk Nöroloji Dergisi / 2007 / Cilt: 13 - Sayı: 6

The relationship between the multiple sclerosis and endogenous antioxidan serum uric acid

Multipl skleroz ve endojen antioksidan serum ürik asit arasındaki ilişki

Pages
409–414
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: In the overall MS group, serum UA levels were significantly lower than in controls (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The Relationship Between the Multiple Sclerosis and Endogenous Antioxidan Serum Uric Acid Scientific background: Peroxynitrite (PRN) is a strong oxidant capable of damaging tissues and cells, and plays a major role in the pathogenesis of multiple sclerosis (MS).
📊
Key Findings & Data:Materials and methods: Serum uric acid levels were determined in 206 MS patients (151 women) all in the remission period, and in 38 age and sex matched voluntary healthy subjects, served as a control group.
💡
Conclusion & Impact:Results: In the overall MS group, serum UA levels were significantly lower than in controls (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The Relationship Between the Multiple Sclerosis and Endogenous Antioxidan Serum Uric Acid Scientific background: Peroxynitrite (PRN) is a strong oxidant capable of damaging tissues and cells, and plays a major role in the pathogenesis of multiple sclerosis (MS). Uric acid (UA) is the naturally occuring final product of the purine metabolism in humans and the most prominent endojen antioxidant in serum. Uric acid selectively binds and inactivates the PRN. Recent studies suggested that patients with multiple sclerosis (MS) have lower levels of serum UA. Objective: To investigate the role of the endogenous antioxidant defence in MS pathogenesis, by determining the serum UA levels of the MS patients and, examining the relationships with demographic and clinical characteristics of the patients. Materials and methods: Serum uric acid levels were determined in 206 MS patients (151 women) all in the remission period, and in 38 age and sex matched voluntary healthy subjects, served as a control group. Of the 206 patients; 159 had the relapsing-remitting (RR) type of the disease, 37 secondary progressive (SP) and 10 primary progressive (PP). Disability as assessed by EDSS (Expanded Disability Status Scale) score. In addition, during the follow up period (12 months), relapses were observed in 45 of the 206 patients. Serum UA levels and EDSS of the patients were also determined in the relapse period before the treatment and, compared with remission period. Results: In the overall MS group, serum UA levels were significantly lower than in controls (p

Özet

Bilimsel zemin: Peroksinitrit (PRN) güçlü bir oksidan olup doku ve hücrelere zarar verir ve multipl sklerozun (MS) patogenezinde major bir rol oynar. Ürik asit (ÜA) insanlarda pürin metabolizmasının doğal olarak oluşan son ürünüdür ve serumda en fazla bulunan endojen antioksidandır. Ürik asit, PRN'ye seçici olarak bağlanıp onu inaktive eder. Yakın dönemde yapılan çalışmalarda MS hastalarında serum ÜA seviyesinin düşük olabileceği öne sürülmektedir. Amaç: Bu çalışmanın amacı, endojen antioksidan savunmanın, MS'nin patogenezindeki rolünü araştırmak için, multipl skleroz hastalarında serum ürik asit düzeylerini belirleyerek, demografik ve klinik özellikler ile olan ilişkisini incelemektir. Gereç ve yöntemler: Ataksız dönemde bulunan 206 MS hastasında (151 kadın) ve 38 yaş ve cins eşleştirilmiş sağlıklı bireyden oluşan kontrol grubunda, serum ÜA değerleri belirlendi. Klinik alt tiplerine göre 206 hastanın; 159'u relapsing remitting (RR-MS), 37'si sekonder progresif (SP-MS) ve 10 hasta da primer progresif (PP-MS) formunda idi. Hastaların dizabiliteleri EDSS (Expanded Disability Status Scale) skoru ile değerlendirildi. Hastalar 12 ay boyunca takip edildi ve bu süre içinde 206 hastanın 45'inde atak gözlendi. Atak gözlenen hastalarda tedaviden hemen önce serum ÜA seviyeleri ve EDSS değerleri belirlenerek ataksız dönem ile karşılaştırıldı. Sonuçlar: Multipl skleroz hastalarında, serum ürik asidi kontrol grubuna göre anlamlı düşük bulundu (p

🔖

Cite This Article

YILMAZ, Z., CANDAN, F., YILDIZ, N., CANTÜRK, A. İ., GÜRER, R., IŞIK, N. (2022). The relationship between the multiple sclerosis and endogenous antioxidan serum uric acid. Türk Nöroloji Dergisi, Cilt: 13 - Sayı: 6, 409–414. https://ajindex.com/articles/637092

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Miller AE, Lublin FD, Coyle PK. Multiple sclerosis in clinical practice. London: Martin Dunitz; 2003:1-14, 31-53
  2. Rowland PL. Merritt's neurology. Tenth edition. Philadelphia: Lippincott W.W; 2000:773-792
  3. Bradley WG, Daroff RB, Fenichel GM, Marsden CD. Neurology in clinical practice. Third edition. Boston: Butterworth H.; 2000:1431-1465
  4. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal Transection in the Lesions of the Multiple Sclerosis. N Engl J Med. 1998;278-85
  5. Koprowski H, Spitsin SV, Hooper DC. Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite. Ann Neurol 2001;1:139
  6. Cross AH, Manning PT, Keeling RM, Schmidt RE, Misko TP. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 1998;8:45-56
  7. Hill KE, Zollinger LV, Watt HE, Carlson NG, Rose JW. Inducible nitric oxide synthase in chronic active multiple sclerosis plaques: distribution, cellular expression and association with myelin damage. J Neuroimmunol 2004;6:171-9
  8. Skinner KA, White CR, Patel R, et al. Nitrosation of Uric Acid by Peroxynitrite. J Biol Chem 1998;9;24491-24497
  9. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1998; 1:675-680
  10. Toncev G, Milicic B, Toncev S, Samardzic G. High-dose methylprednisolone therapy in multiple sclerosis increases serum uric acid levels. Clin Chem Lab Med 2002;5:505-8
  11. Burtis CA, Ashwood ER. Tietz textbook of clinical chemistry. Third edition. Philadelphia: W.B. Saunders; 1999:1245-1250
  12. Becker BF. Towards the physiological function of uric acid. Free Radical Biol Med 1993;6:615-631
  13. Waring WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 2001;9:365-371
  14. Spitsin SV, Scott GS, Kean RB, Mikheeva T, Hooper DC. Protection of myelin basic protein immunized mice from free-radical mediated inflammatory cell invasion of the central nervous system by the natural peroxynitrite scavenger uric acid. Neurosci Lett 2000; 10:137-41
  15. Drulovic J, Dujmovic I, Stojsavljevic N, et al. Uric acid levels in sera from patients with multiple sclerosis. J Neural 2001;2:121-6
  16. Spitsin SV, Scott GS, Mikheeva T, et al. Comparison of uric acid and ascorbic acid in protec